Risk factors and prognostic significance of infection of totally implantable vascular access port in solid tumor patients: A prospective cohort study.

Infection Mortality Risk factors Solid tumor Totally Implantable Vascular Access Port

Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 04 05 2023
revised: 21 07 2023
accepted: 27 07 2023
pubmed: 6 8 2023
medline: 6 8 2023
entrez: 5 8 2023
Statut: ppublish

Résumé

Totally implantable venous access ports (TIVAP) are devices mainly used to deliver antineoplastic chemotherapies, of which the insertion may be complicated by TIVAP-related infection (TIVAP-RI). This study aims to provide data on the risk factors for TIVAP-RI and its influence on patient prognosis. Prospective observational study including adult patients with solid tumors, in whom a TIVAP was inserted to deliver antineoplastic chemotherapy between January 2018 and October 2019. Factors associated with TIVAP-RI and one-year mortality were determined using multiple logistic regressions. More than a thousand (1014) patients were included, among whom 48 (4.7%) presented with TIVAP-RI. Gram-positive cocci and Gram-negative bacilli represented 51% and 41% of the pathogens isolated, respectively. Young age (odds ratio [OR] 0.67; 95% Confidence Interval [0.53-0.83] per 10-year increase), WHO performance status ≥ 1 (OR 3.24 [1.52-7.79]), chemotherapy administration in the month before TIVAP placement (OR 2.26 [1.17-4.26]), and radiation therapy of the homolateral chest wall (OR 3.28 [1.51-6.67]) were independently associated with TIVAP-RI occurrence. During the year following TIVAP insertion, 287 (28%) patients died. TIVAP-RI was not associated with one-year mortality (OR 1.56 [0.75-3.19]). TIVAP insertion in adult patients with solid tumors is associated with a low infection rate, which did not influence one-year mortality. In addition to young age and impaired health status, TIVAP insertion in the month following initiation of the antineoplastic chemotherapy and TIVAP insertion in an irradiated area are two newly reported preventable TIVAP-RI risk factors.

Identifiants

pubmed: 37543258
pii: S2666-9919(23)00128-8
doi: 10.1016/j.idnow.2023.104766
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104766

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Amaury Bailleul (A)

Sorbonne Université, AP-HP, GRC29, DMU DREAM, Hôpital Tenon, Service d'Anesthésie-Réanimation et Médecine Périopératoire - 4 rue de la Chine, 75020 Paris, France.

Jean-Pierre Fulgencio (JP)

Sorbonne Université, AP-HP, GRC29, DMU DREAM, Hôpital Tenon, Service d'Anesthésie-Réanimation et Médecine Périopératoire - 4 rue de la Chine, 75020 Paris, France.

Sophie Vimont (S)

Département de Bactériologie, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, - 184 rue du Faubourg Saint-Antoine, 75012 Paris, France; Sorbonne Université, INSERM UMR S_1155, Hôpital Tenon, Paris, France.

Cécile Mordelet (C)

Sorbonne Université, AP-HP, GRC29, DMU DREAM, Hôpital Tenon, Service d'Anesthésie-Réanimation et Médecine Périopératoire - 4 rue de la Chine, 75020 Paris, France.

Benoit Ray (B)

Sorbonne Université, AP-HP, GRC29, DMU DREAM, Hôpital Tenon, Service d'Anesthésie-Réanimation et Médecine Périopératoire - 4 rue de la Chine, 75020 Paris, France.

Ludovic Lassel (L)

Sorbonne Université, AP-HP, DMU 3ID, Hôpital Tenon, Service des Maladies Infectieuses et Tropicales - 4 rue de la Chine, 75020 Paris, France.

Nathanaël Lapidus (N)

Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Saint-Antoine Hospital, Public Health Department, 75012 Paris, France.

Christophe Quesnel (C)

Sorbonne Université, AP-HP, GRC29, DMU DREAM, Hôpital Tenon, Service d'Anesthésie-Réanimation et Médecine Périopératoire - 4 rue de la Chine, 75020 Paris, France.

Marc Garnier (M)

Sorbonne Université, AP-HP, GRC29, DMU DREAM, Hôpital Tenon, Service d'Anesthésie-Réanimation et Médecine Périopératoire - 4 rue de la Chine, 75020 Paris, France; Université Clermont-Auvergne, CHU de Clermont-Ferrand, Service d'Anesthésie-Réanimation et Médecine Périopératoire, 58 rue Montalembert, 63000 Clermont-Ferrand, France. Electronic address: mgarnier@chu-clermontferrand.fr.

Classifications MeSH